Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDGE-Lung: Immunotherapy-based Combinations in Advanced Non-Small Cell Lung Cancer
NCT05676931Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of domvanalimab, quemliclustat and zimberelimab in non-small cell lung cancer (NSCLC) (10 arms), sponsored by Gilead Sciences. Primary endpoints: Objective Response Rate up to 58 months and Incidence and Severity of Adverse Events and Serious Adverse Events up to 58 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
domvanalimabquemliclustatzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05676931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676931.